Flibanserin
| Code | Size | Price |
|---|
| CDX-F0337-M005 | 5 mg | £59.00 |
Quantity:
| CDX-F0337-M025 | 25 mg | £157.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
Ambient
Storage:
+4°C
Documents
Further Information
Alternate Names/Synonyms:
1,3-Dihydro-1-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]-2H-benzimidazol-2-one; BIMT 17; BIMT 17BS
Appearance:
White to beige powder.
CAS:
167933-07-5
Class:
6.1
EClass:
32160000
Form (Short):
liquid
GHS Symbol:
GHS06
Handling Advice:
Protect from light and moisture.
Hazards:
H301, H315, H319, H335
InChi:
InChI=1S/C20H21F3N4O/c21-20(22,23)15-4-3-5-16(14-15)26-11-8-25(9-12-26)10-13-27-18-7-2-1-6-17(18)24-19(27)28/h1-7,14H,8-13H2,(H,24,28)
InChiKey:
PPRRDFIXUUSXRA-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 167933-07-5. Formula: C20H21F3N4O. MW: 390.4. Synthetic. Flibanserin is a full agonist of the serotonin 5-HT1A receptor and an antagonist of 5-HT2A (Ki=1nm and 49nM, respectively). It also binds to dopamine D4 receptors with Ki values ranging from 4-24nM, but demonstrates no affinity for the other 5-HT subtypes or other neurotransmitter receptors. Multifunctional serotonergic ligands like flibanserin that can enhance downstream release of dopamine and norepinephrine while concomitantly reducing serotonin release in the brain circuits that mediate symptoms of reduced sexual interest and desire, are being studied clinically for therapeutic potential to improve sexual functioning. Flibanserin was investigated as a novel, non-hormonal treatment for pre-menopausal women with Hypoactive Sexual Desire Disorder (HSDD). Flibanserin was also found to reduce L-DOPA-induced dyskinesia in a model of Parkinson's Disease.
MDL:
MFCD00918402
Molecular Formula:
C20H21F3N4O
Molecular Weight:
390.4
Package Type:
Vial
PG:
III
Precautions:
P261, P301+310, P305+351+338
Product Description:
Flibanserin is a full agonist of the serotonin 5-HT1A receptor and an antagonist of 5-HT2A (Ki=1nm and 49nM, respectively). It also binds to dopamine D4 receptors with Ki values ranging from 4-24nM, but demonstrates no affinity for the other 5-HT subtypes or other neurotransmitter receptors. Multifunctional serotonergic ligands like flibanserin that can enhance downstream release of dopamine and norepinephrine while concomitantly reducing serotonin release in the brain circuits that mediate symptoms of reduced sexual interest and desire, are being studied clinically for therapeutic potential to improve sexual functioning. Flibanserin was investigated as a novel, non-hormonal treatment for pre-menopausal women with Hypoactive Sexual Desire Disorder (HSDD). Flibanserin was also found to reduce L-DOPA-induced dyskinesia in a model of Parkinson's Disease.
Purity:
>98% (HPLC)
Signal word:
Danger
SMILES:
O=C1NC2=CC=CC=C2N1CCN3CCN(C4=CC=CC(C(F)(F)F)=C4)CC3
Solubility Chemicals:
Soluble in DMSO (20mg/ml), DMF (20mg/ml) or ethanol (10mg/ml)
Source / Host:
Synthetic
Transportation:
Excepted Quantity
UN Nummer:
2810
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at +4°C.
References
(1) F. Borsini, et al.; Naunyn Schmiedebergs Arch. Pharmacol. 352, 276 (1995) | (2) F. Borsini, et al.; Naunyn Schmiedebergs Arch. Pharmacol. 352, 283 (1995) | (3) F. Borsini, et al.; Psychopharmacology 134, 378 (1997) | (4) A. Scandroglio, et al.; Pharmacol. Res. 43, 179 (2001) | (5) F. Borsini, et al.; CNS Drug Rev. 8, 117 (2002) (Review) | (6) R.W. Invernizzi, et al.; Br. J. Pharmacol. 139, 1281 (2003) | (7) H. Gelez, et al.; J. Sex. Med. 10, 1231 (2013) | (8) S.M. Stahl; CNS Spectr. 20, 1 (2015) (Review) | (9) I. Dhanuka & J.A. Simon; Expert Opin. Pharmacother. 16, 2523 (2015) (Review)